Letrozole for Fertility in New Jersey | Damien Fertility Partners
Letrozole is currently the first-line oral medication for ovulation induction in women with polycystic ovary syndrome (PCOS). It displaced clomiphene citrate from that role following a landmark randomized controlled trial published in the New England Journal of Medicine, which found letrozole produced cumulative live birth rates of 27.5% in women with PCOS — compared to 19.1% for clomiphene, a clinically meaningful difference that led the American Society for Reproductive Medicine to revise its clinical guidelines in favor of letrozole.
Patients starting letrozole have practical questions: how it works, who it’s appropriate for, what to expect cycle by cycle, and when to consider moving to a more advanced treatment. Those are the questions this page addresses.
Damien Fertility Partners has provided ovulation induction and fertility care across New Jersey since 1989, with offices in Shrewsbury (Monmouth County), Newark (Essex County), and Jersey City (Hudson County). All letrozole cycles are monitored in-house — transvaginal ultrasound and bloodwork are performed by the same ABOG board-certified reproductive endocrinologist managing your care, not a rotating provider or separate monitoring center.
Letrozole
Letrozole is an aromatase inhibitor. Aromatase is the enzyme that converts androgens into estrogen in the body. By temporarily blocking this enzyme, letrozole causes a short-term drop in circulating estrogen. That drop signals the pituitary gland to release more follicle-stimulating hormone (FSH). The FSH surge then stimulates the ovaries to develop one or more follicles, each containing a potential egg.
The mechanism is self-limiting. Letrozole is metabolized and cleared from the body relatively quickly — its half-life is approximately 45 hours. After the medication course ends, estrogen rebounds naturally, which reinforces follicle maturation and helps trigger ovulation. Because the anti-estrogenic effect dissipates before the implantation window, letrozole does not thin the uterine lining or reduce cervical mucus the way clomiphene does. That distinction matters clinically: a more favorable uterine environment at the time of ovulation improves conditions for implantation.
Letrozole is FDA-approved as a breast cancer treatment. Its use in fertility is off-label — meaning it is prescribed for a purpose supported by strong clinical evidence but not originally included in the FDA approval. Off-label prescribing is common in reproductive medicine and is explicitly supported by ASRM clinical guidelines for ovulation induction.
Who Letrozole Is Prescribed For
PCOS with ovulatory dysfunction. Letrozole is the preferred first-line treatment for women with PCOS who are not ovulating regularly. PCOS is one of the most common causes of ovulatory infertility, affecting an estimated 6–12% of reproductive-age women in the U.S. For this group, the NEJM trial data — 61.7% ovulation rate per cycle with letrozole versus 48.3% with clomiphene — represents a clear clinical basis for the preference.
Unexplained infertility. Letrozole is used in women with unexplained infertility who ovulate normally, as a form of controlled ovarian stimulation (COS). The goal is to develop one or two additional follicles in a given cycle, increasing the probability of conception. COS with letrozole is frequently combined with intrauterine insemination (IUI) rather than timed intercourse, which improves per-cycle outcomes.
Irregular ovulation from other causes. Women with ovulatory dysfunction not attributable to PCOS — including hypothalamic amenorrhea and other cycle irregularities — may also be candidates, depending on their specific hormonal picture and clinical history.
Your board-certified physician will assess your hormone levels, cycle history, and diagnosis before recommending letrozole. It is not appropriate for every patient, and the protocol is individualized to your clinical profile.
Letrozole vs. Clomiphene
Clomiphene citrate (brand name Clomid) was the standard first-line ovulation induction agent for decades. Letrozole has largely replaced it, particularly for women with PCOS, based on the evidence from multiple well-designed clinical trials.
The two medications work through different mechanisms. Clomiphene blocks estrogen receptors for a prolonged period — up to several weeks — which suppresses estrogen signaling in the uterus and cervix throughout the cycle. This prolonged anti-estrogenic effect can thin the uterine lining and reduce cervical mucus production, both of which matter for implantation and sperm transport.
Letrozole’s shorter half-life means estrogen levels recover before the implantation window. The uterine lining is generally thicker, and cervical mucus is less affected. For many patients, this translates into better implantation conditions at equivalent ovulation rates.
The NEJM trial is the most frequently cited evidence: 27.5% cumulative live birth rate with letrozole versus 19.1% with clomiphene in women with PCOS. That gap — 8.4 percentage points across a full treatment course — represents a meaningful clinical difference, not a marginal one.
Letrozole Cycle
Letrozole is taken orally once daily for five days, typically beginning on cycle day 3, 4, or 5, depending on your protocol. The medication course is short; most patients complete it within the first week of their cycle.
Monitoring. After completing the five-day course, your physician will schedule a transvaginal ultrasound to assess follicle development. The scan typically occurs around cycle day 10–14, depending on your response. It measures the number and size of developing follicles and assesses uterine lining thickness. Bloodwork — including estradiol and LH levels — may be drawn alongside imaging to optimize timing.
Trigger and timing. When one or more follicles reach the target size (typically 18–22 mm), a trigger shot — usually hCG — may be administered to time final egg maturation precisely. If you are combining letrozole with IUI, the insemination is scheduled approximately 24–36 hours after the trigger.
Cycle assessment. If ovulation is confirmed but pregnancy does not result, the cycle is reviewed before proceeding. Dose adjustments, protocol modifications, or a recommendation to move to IVF are all possible depending on your response and cumulative history.
All monitoring at our practice is performed in-house. The same physician reviews your results each visit.
Success Rates and Realistic Expectations
Letrozole outcomes vary by diagnosis, age, and treatment approach. Per-cycle success rates differ significantly depending on what is being treated.
PCOS. The strongest evidence comes from the NEJM randomized controlled trial: 27.5% cumulative live birth rate over multiple cycles with letrozole, versus 19.1% with clomiphene. Ovulation occurred in approximately 61.7% of letrozole cycles versus 48.3% with clomiphene. These figures represent the best-available population-level data for this group.
Unexplained infertility with IUI. For patients with unexplained infertility combining letrozole with IUI, per-cycle pregnancy rates are typically in the 10–20% range, depending on age and other clinical factors. Success is largely cumulative. Most physicians recommend three to six monitored cycles before reassessing, as the probability of conception builds meaningfully across attempts.
Older patients and diminished ovarian reserve. Per-cycle rates are generally lower for women over 38 or those with diminished ovarian reserve. In these cases, the threshold for advancing to IVF is typically lower, based on ASRM guidelines supporting earlier escalation when age-related urgency is a factor.
In 2023, we reported an 81.8% live-birth rate per new patient for women under 35 who proceeded to IVF, as submitted through SART. Clinic-to-clinic comparisons should be interpreted with caution due to differences in patient populations. Full outcomes data is available on the SART website and our success rates page.
Multiple Pregnancy Risk
Letrozole carries a lower multiple pregnancy risk than injectable gonadotropins. It typically stimulates one or two follicles, which means most letrozole pregnancies are singletons. The estimated twin rate is roughly 3–7% — elevated compared to the natural conception rate, but substantially below the rates associated with aggressive stimulation protocols.
If a monitoring ultrasound reveals excessive follicle development, your physician will review the options: adjusting the dose for the next cycle, canceling the current cycle, or converting to IVF to maintain control over the number of embryos transferred. Monitoring is the mechanism by which this risk is managed — which is why in-house, cycle-by-cycle oversight matters.
Side Effects
Most patients tolerate letrozole well. Common side effects include mild headaches, fatigue, hot flashes, and occasional mood changes. Most resolve once the five-day medication course ends. Because letrozole clears the system quickly, side effects tend to be short-lived relative to clomiphene, which remains active in the body much longer.
Early studies raised theoretical concerns about birth defects with letrozole use in pregnancy. Subsequent large-scale research has not confirmed an elevated risk. Ovarian hyperstimulation syndrome (OHSS) — a potentially serious side effect of injectable gonadotropins — is rare with letrozole. Your physician will review your individual health history before recommending any protocol.
The Physicians Managing Your Care
Dr. Miguel Damien founded the practice in 1989 — originally as East Coast IVF, establishing New Jersey’s first successful IVF program in Monmouth and Ocean County. He is a Dartmouth Medical School graduate who completed his OB/GYN residency and REI fellowships at Harvard Medical School and the University of Connecticut. Board-certified in REI by ABOG and fluent in Spanish, he has been named a Castle Connolly Top Doctor in the NY Metro Area six times (2005, 2007, 2008, 2010, 2017, 2018).
Dr. Barry Perlman is an ABOG board-certified REI specialist and Fellow of the American College of Obstetricians and Gynecologists (ACOG). A published researcher on endocrine disruptors and fertility, he has been named a Castle Connolly Top Doctor five times. He joined our practice in 2023 and offers both in-person and virtual consultations.
Frequently Asked Questions
1. Is letrozole FDA-approved for fertility treatment?
Letrozole is FDA-approved as a breast cancer treatment. Its use in fertility is off-label — prescribed for a purpose supported by strong clinical evidence but not included in the original FDA approval. Off-label prescribing is standard in reproductive medicine. The American Society for Reproductive Medicine endorses letrozole as the preferred first-line therapy for ovulation induction in women with PCOS.
2. How many letrozole cycles should I try before moving on?
Most specialists recommend three to six monitored cycles before considering a protocol change. The appropriate threshold depends on your age, diagnosis, and ovulatory response. Women over 35, or those not responding to standard doses, may reach the decision point for IVF sooner. Your physician will review your cumulative response before making that recommendation.
3. Can letrozole be used if I already ovulate?
Yes. Letrozole can be used in women who ovulate normally as a form of controlled ovarian stimulation — developing one or two additional follicles to increase the probability of conception in a given cycle. This approach is frequently combined with IUI for patients with unexplained infertility. Per-cycle pregnancy rates are typically in the 10–20% range with this combination, depending on age and other factors.
4. What is the twin risk with letrozole?
The estimated twin rate with letrozole is roughly 3–7%. That is elevated relative to natural conception, but substantially lower than the multiple pregnancy risk associated with injectable gonadotropins. Letrozole typically stimulates one or two follicles, which limits the risk. Cycle monitoring with transvaginal ultrasound allows your physician to intervene if excessive follicle development occurs.
5. When does ovulation occur after taking letrozole?
Most women ovulate approximately 7–10 days after completing the five-day letrozole course. A monitoring ultrasound is typically scheduled around cycle day 10–14 to confirm follicle development and time an IUI or trigger shot for optimal results.
6. What happens if letrozole doesn’t produce ovulation or pregnancy?
A lack of response to letrozole is clinically useful information — it helps guide the next step. Options include increasing the dose in a subsequent cycle, adding an injectable trigger, combining letrozole with IUI if not already doing so, or advancing to IVF. The ASRM supports earlier escalation to IVF when age-related urgency or prior treatment failure makes continued oral induction unlikely to succeed.
Schedule a Consultation with Dr. Damien or Dr. Perlman
Letrozole is one part of a broader evaluation and treatment plan. The appropriate dose, monitoring schedule, and decision point for escalating to IUI or IVF all depend on your specific diagnosis, hormone profile, age, and treatment history.
We see patients at our offices in Shrewsbury (Monmouth County), Newark (Essex County), and Jersey City (Hudson County). Dr. Perlman offers virtual consultations for patients who prefer to begin remotely. We provide care to individuals and couples of all backgrounds, with no BMI-based limitations and dedicated support for LGBTQ+ patients. Spanish-speaking providers are available at all three offices.
Visit damienfertilitypartners.com or call (732) 758-6511 to request a consultation with Dr. Damien or Dr. Perlman.